Timothy Garrington
Concepts (323)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Central Nervous System Neoplasms | 2 | 2024 | 177 | 0.650 |
Why?
| | Rhabdomyosarcoma | 1 | 2019 | 65 | 0.540 |
Why?
| | Sarcoma, Ewing | 3 | 2025 | 103 | 0.540 |
Why?
| | MAP Kinase Kinase Kinases | 6 | 2004 | 70 | 0.490 |
Why?
| | Kidney Neoplasms | 4 | 2025 | 419 | 0.470 |
Why?
| | Mitogen-Activated Protein Kinases | 8 | 2004 | 288 | 0.390 |
Why?
| | Hodgkin Disease | 2 | 2016 | 173 | 0.360 |
Why?
| | Wilms Tumor | 2 | 2025 | 91 | 0.330 |
Why?
| | Neuroblastoma | 3 | 2017 | 177 | 0.300 |
Why?
| | Mitogen-Activated Protein Kinase Kinases | 4 | 2004 | 126 | 0.290 |
Why?
| | Beckwith-Wiedemann Syndrome | 1 | 2008 | 7 | 0.290 |
Why?
| | Adrenal Gland Neoplasms | 2 | 2014 | 99 | 0.280 |
Why?
| | Fluorodeoxyglucose F18 | 1 | 2009 | 164 | 0.280 |
Why?
| | Neoplasms | 6 | 2025 | 2954 | 0.270 |
Why?
| | Neoplasms, Multiple Primary | 1 | 2008 | 57 | 0.270 |
Why?
| | Asparaginase | 2 | 1998 | 34 | 0.270 |
Why?
| | JNK Mitogen-Activated Protein Kinases | 5 | 2004 | 153 | 0.270 |
Why?
| | MAP Kinase Kinase Kinase 1 | 3 | 2005 | 19 | 0.260 |
Why?
| | Adrenal Cortex Neoplasms | 1 | 2008 | 70 | 0.260 |
Why?
| | Positron-Emission Tomography | 1 | 2009 | 343 | 0.260 |
Why?
| | Histiocytosis, Langerhans-Cell | 2 | 2020 | 36 | 0.260 |
Why?
| | Child | 25 | 2025 | 22693 | 0.250 |
Why?
| | Pancreatitis | 2 | 1998 | 146 | 0.250 |
Why?
| | MAP Kinase Kinase Kinase 2 | 7 | 2012 | 12 | 0.230 |
Why?
| | Teratoma | 2 | 2025 | 121 | 0.230 |
Why?
| | Child, Preschool | 18 | 2025 | 11913 | 0.230 |
Why?
| | Mast Cells | 3 | 2003 | 150 | 0.220 |
Why?
| | Testicular Neoplasms | 2 | 2017 | 108 | 0.220 |
Why?
| | Nose Neoplasms | 1 | 2025 | 22 | 0.220 |
Why?
| | Adaptor Proteins, Signal Transducing | 4 | 2003 | 429 | 0.220 |
Why?
| | Carcinosarcoma | 1 | 2025 | 23 | 0.220 |
Why?
| | Genetic Heterogeneity | 1 | 2025 | 67 | 0.210 |
Why?
| | Clonal Evolution | 1 | 2025 | 47 | 0.210 |
Why?
| | Appointments and Schedules | 1 | 2025 | 97 | 0.210 |
Why?
| | Paclitaxel | 1 | 2025 | 260 | 0.200 |
Why?
| | Adolescent | 20 | 2025 | 22557 | 0.200 |
Why?
| | Medical Errors | 1 | 2025 | 124 | 0.200 |
Why?
| | Fibroblast Growth Factor 2 | 1 | 2004 | 93 | 0.200 |
Why?
| | Hematology | 1 | 2023 | 21 | 0.190 |
Why?
| | Catheterization, Central Venous | 1 | 2025 | 121 | 0.190 |
Why?
| | Neoplasms, Germ Cell and Embryonal | 2 | 2016 | 76 | 0.190 |
Why?
| | Biomarkers, Tumor | 3 | 2025 | 1339 | 0.190 |
Why?
| | Central Nervous System Diseases | 1 | 2024 | 73 | 0.190 |
Why?
| | MAP Kinase Signaling System | 3 | 2008 | 307 | 0.190 |
Why?
| | Neoplasms, Second Primary | 1 | 2024 | 103 | 0.190 |
Why?
| | Pediatrics | 3 | 2023 | 1124 | 0.180 |
Why?
| | Parental Leave | 1 | 2022 | 27 | 0.180 |
Why?
| | Bone Neoplasms | 1 | 2025 | 272 | 0.180 |
Why?
| | Lung Neoplasms | 2 | 2021 | 2675 | 0.180 |
Why?
| | Calcium-Calmodulin-Dependent Protein Kinases | 2 | 1999 | 165 | 0.170 |
Why?
| | Anemia | 1 | 2023 | 190 | 0.170 |
Why?
| | Single-Cell Analysis | 1 | 2025 | 370 | 0.170 |
Why?
| | Thrombocytopenia | 1 | 2023 | 206 | 0.170 |
Why?
| | Medical Oncology | 2 | 2023 | 345 | 0.170 |
Why?
| | Pulmonary Blastoma | 1 | 2021 | 8 | 0.170 |
Why?
| | Sarcoma | 2 | 2015 | 209 | 0.160 |
Why?
| | RNA, Neoplasm | 1 | 2021 | 76 | 0.160 |
Why?
| | Pituitary Diseases | 1 | 2020 | 20 | 0.160 |
Why?
| | Stem Cell Factor | 1 | 2000 | 16 | 0.160 |
Why?
| | Program Evaluation | 2 | 2023 | 952 | 0.160 |
Why?
| | Ribonuclease III | 1 | 2021 | 44 | 0.160 |
Why?
| | Tomography, X-Ray Computed | 2 | 2021 | 2786 | 0.160 |
Why?
| | Cholestasis | 1 | 2023 | 217 | 0.160 |
Why?
| | Receptors, IgE | 1 | 2000 | 43 | 0.160 |
Why?
| | Circulating Tumor DNA | 1 | 2021 | 50 | 0.160 |
Why?
| | Sertoli-Leydig Cell Tumor | 1 | 2020 | 8 | 0.160 |
Why?
| | Rhabdomyosarcoma, Embryonal | 1 | 2020 | 16 | 0.160 |
Why?
| | DEAD-box RNA Helicases | 1 | 2021 | 90 | 0.160 |
Why?
| | Pituitary Gland | 1 | 2020 | 148 | 0.150 |
Why?
| | Fibroblasts | 3 | 2005 | 1034 | 0.150 |
Why?
| | Infant | 12 | 2025 | 10114 | 0.150 |
Why?
| | Lymphohistiocytosis, Hemophagocytic | 1 | 2020 | 33 | 0.150 |
Why?
| | Humans | 40 | 2025 | 146342 | 0.150 |
Why?
| | Survival Rate | 3 | 2019 | 2092 | 0.140 |
Why?
| | Salvage Therapy | 2 | 2025 | 166 | 0.140 |
Why?
| | Fellowships and Scholarships | 1 | 2022 | 355 | 0.140 |
Why?
| | Proto-Oncogene Proteins B-raf | 1 | 2020 | 231 | 0.140 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2025 | 1160 | 0.140 |
Why?
| | Disease-Free Survival | 2 | 2019 | 778 | 0.140 |
Why?
| | Polycystic Kidney Diseases | 1 | 2019 | 82 | 0.140 |
Why?
| | Octreotide | 1 | 1998 | 23 | 0.130 |
Why?
| | Biopsy, Large-Core Needle | 1 | 2017 | 15 | 0.130 |
Why?
| | Female | 23 | 2025 | 79499 | 0.130 |
Why?
| | Male | 23 | 2025 | 73396 | 0.130 |
Why?
| | Abdominal Neoplasms | 1 | 2017 | 48 | 0.130 |
Why?
| | Antibodies, Neutralizing | 1 | 2020 | 348 | 0.130 |
Why?
| | Cytodiagnosis | 1 | 2017 | 31 | 0.120 |
Why?
| | Frozen Sections | 1 | 2017 | 23 | 0.120 |
Why?
| | Seminoma | 1 | 2017 | 20 | 0.120 |
Why?
| | Interferon-gamma | 1 | 2020 | 781 | 0.120 |
Why?
| | Cytokines | 2 | 2004 | 2081 | 0.120 |
Why?
| | Tumor Necrosis Factor-alpha | 4 | 2003 | 1224 | 0.120 |
Why?
| | Enzyme Activation | 6 | 2004 | 759 | 0.120 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 2 | 2025 | 1998 | 0.120 |
Why?
| | Cancer Survivors | 1 | 2022 | 348 | 0.120 |
Why?
| | Protein Processing, Post-Translational | 1 | 1999 | 487 | 0.120 |
Why?
| | Quality Improvement | 1 | 2025 | 1354 | 0.120 |
Why?
| | Health Planning | 1 | 2015 | 46 | 0.110 |
Why?
| | Saccharomyces cerevisiae Proteins | 1 | 1999 | 411 | 0.110 |
Why?
| | Retrospective Studies | 8 | 2025 | 17438 | 0.110 |
Why?
| | Transcription Factor AP-1 | 2 | 2005 | 76 | 0.100 |
Why?
| | Thoracoscopy | 1 | 2014 | 60 | 0.100 |
Why?
| | Mediastinal Neoplasms | 1 | 2014 | 54 | 0.100 |
Why?
| | Ovarian Neoplasms | 1 | 2020 | 604 | 0.100 |
Why?
| | Biopsy | 1 | 2017 | 1075 | 0.100 |
Why?
| | Arabinonucleosides | 1 | 2013 | 8 | 0.100 |
Why?
| | Adenine Nucleotides | 1 | 2013 | 21 | 0.100 |
Why?
| | Xanthogranuloma, Juvenile | 1 | 2013 | 6 | 0.100 |
Why?
| | Carrier Proteins | 4 | 2003 | 728 | 0.100 |
Why?
| | Genetic Predisposition to Disease | 2 | 2021 | 2488 | 0.100 |
Why?
| | Histiocytosis, Sinus | 1 | 2013 | 7 | 0.100 |
Why?
| | Disease Management | 2 | 2015 | 651 | 0.100 |
Why?
| | Transition to Adult Care | 1 | 2015 | 111 | 0.100 |
Why?
| | Antimetabolites, Antineoplastic | 1 | 2013 | 108 | 0.090 |
Why?
| | Ambulatory Care Facilities | 1 | 2015 | 269 | 0.090 |
Why?
| | Antibodies, Monoclonal | 1 | 2020 | 1512 | 0.090 |
Why?
| | Heart Diseases | 1 | 2016 | 343 | 0.090 |
Why?
| | Hypertrophy, Right Ventricular | 1 | 2012 | 151 | 0.090 |
Why?
| | Prognosis | 5 | 2025 | 4351 | 0.090 |
Why?
| | Prevalence | 1 | 2019 | 2861 | 0.090 |
Why?
| | Diagnostic Imaging | 1 | 2014 | 340 | 0.090 |
Why?
| | Gene Expression Regulation | 4 | 2012 | 2599 | 0.090 |
Why?
| | Receptors, Tumor Necrosis Factor | 2 | 2002 | 162 | 0.080 |
Why?
| | Anesthesia | 1 | 2014 | 257 | 0.080 |
Why?
| | Program Development | 2 | 2015 | 371 | 0.080 |
Why?
| | Signal Transduction | 3 | 2004 | 5246 | 0.080 |
Why?
| | Ventricular Remodeling | 1 | 2012 | 283 | 0.080 |
Why?
| | Stem Cells | 2 | 2008 | 613 | 0.080 |
Why?
| | Subtraction Technique | 1 | 2009 | 26 | 0.080 |
Why?
| | Laparoscopy | 1 | 2014 | 487 | 0.070 |
Why?
| | Primary Health Care | 2 | 2022 | 1776 | 0.070 |
Why?
| | Young Adult | 7 | 2025 | 14330 | 0.070 |
Why?
| | Radiopharmaceuticals | 1 | 2009 | 210 | 0.070 |
Why?
| | Potassium Channels, Voltage-Gated | 1 | 2008 | 54 | 0.070 |
Why?
| | Mutation | 4 | 2025 | 4093 | 0.070 |
Why?
| | Myocytes, Cardiac | 1 | 2012 | 544 | 0.070 |
Why?
| | Polymerase Chain Reaction | 2 | 2021 | 1031 | 0.070 |
Why?
| | Heart Ventricles | 1 | 2012 | 762 | 0.060 |
Why?
| | Adult | 7 | 2025 | 41087 | 0.060 |
Why?
| | Antineoplastic Agents | 1 | 1998 | 2219 | 0.060 |
Why?
| | Embryo, Mammalian | 2 | 2005 | 230 | 0.060 |
Why?
| | Infant, Newborn | 4 | 2023 | 6460 | 0.060 |
Why?
| | Mitogen-Activated Protein Kinase 7 | 4 | 2012 | 16 | 0.060 |
Why?
| | Leukemia | 1 | 2008 | 246 | 0.060 |
Why?
| | Liver Neoplasms | 1 | 2012 | 776 | 0.060 |
Why?
| | Risk Assessment | 1 | 2015 | 3712 | 0.060 |
Why?
| | Epidermal Growth Factor | 2 | 2003 | 157 | 0.060 |
Why?
| | Near Miss, Healthcare | 1 | 2025 | 12 | 0.060 |
Why?
| | Cell Line | 5 | 2003 | 2814 | 0.060 |
Why?
| | Age Factors | 3 | 2018 | 3347 | 0.060 |
Why?
| | Acute Disease | 2 | 1998 | 1038 | 0.050 |
Why?
| | Proto-Oncogene Proteins c-jun | 1 | 2005 | 51 | 0.050 |
Why?
| | Hypoxia | 1 | 2012 | 1211 | 0.050 |
Why?
| | Transcription Factors | 2 | 2021 | 1730 | 0.050 |
Why?
| | Education, Medical, Undergraduate | 1 | 2007 | 208 | 0.050 |
Why?
| | Cord Blood Stem Cell Transplantation | 1 | 2005 | 103 | 0.050 |
Why?
| | Killer Cells, Natural | 1 | 2008 | 481 | 0.050 |
Why?
| | SEER Program | 2 | 2016 | 233 | 0.050 |
Why?
| | Neoplastic Cells, Circulating | 1 | 2025 | 81 | 0.050 |
Why?
| | Phosphorylation | 3 | 2012 | 1724 | 0.050 |
Why?
| | MAP Kinase Kinase 4 | 1 | 2004 | 24 | 0.050 |
Why?
| | Apoptosis | 3 | 2002 | 2439 | 0.050 |
Why?
| | DNA Copy Number Variations | 1 | 2025 | 192 | 0.050 |
Why?
| | Antineoplastic Agents, Phytogenic | 1 | 2025 | 178 | 0.050 |
Why?
| | Blotting, Western | 2 | 2004 | 1177 | 0.050 |
Why?
| | Genes, jun | 1 | 2003 | 9 | 0.050 |
Why?
| | Myogenic Regulatory Factors | 1 | 2003 | 45 | 0.050 |
Why?
| | Neoplasm Metastasis | 2 | 2018 | 693 | 0.050 |
Why?
| | Survival Analysis | 2 | 2018 | 1378 | 0.050 |
Why?
| | Fluorescent Antibody Technique | 1 | 2004 | 345 | 0.050 |
Why?
| | DNA Methylation | 1 | 2008 | 725 | 0.050 |
Why?
| | beta Catenin | 1 | 2025 | 250 | 0.050 |
Why?
| | Macromolecular Substances | 2 | 2003 | 205 | 0.050 |
Why?
| | Sequence Analysis, RNA | 1 | 2025 | 441 | 0.050 |
Why?
| | Promoter Regions, Genetic | 3 | 2005 | 1242 | 0.050 |
Why?
| | src-Family Kinases | 1 | 2003 | 93 | 0.050 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2005 | 299 | 0.040 |
Why?
| | Tissue Donors | 1 | 2005 | 425 | 0.040 |
Why?
| | Mice | 6 | 2012 | 18297 | 0.040 |
Why?
| | Animals | 9 | 2012 | 38107 | 0.040 |
Why?
| | Mice, Knockout | 2 | 2012 | 3125 | 0.040 |
Why?
| | Recurrence | 3 | 2013 | 1133 | 0.040 |
Why?
| | Cell Differentiation | 2 | 2000 | 1982 | 0.040 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2004 | 846 | 0.040 |
Why?
| | Survivors | 2 | 2016 | 526 | 0.040 |
Why?
| | Academic Medical Centers | 1 | 2025 | 561 | 0.040 |
Why?
| | Cells, Cultured | 3 | 2005 | 4118 | 0.040 |
Why?
| | Protein-Tyrosine Kinases | 2 | 2008 | 429 | 0.040 |
Why?
| | Central Nervous System | 1 | 2024 | 278 | 0.040 |
Why?
| | Databases, Factual | 2 | 2018 | 1493 | 0.040 |
Why?
| | Proto-Oncogene Protein c-fli-1 | 1 | 2021 | 30 | 0.040 |
Why?
| | Survivorship | 1 | 2022 | 62 | 0.040 |
Why?
| | RNA-Binding Protein EWS | 1 | 2021 | 31 | 0.040 |
Why?
| | Hypertension, Pulmonary | 1 | 2012 | 1957 | 0.040 |
Why?
| | Kidney Diseases, Cystic | 1 | 2021 | 24 | 0.040 |
Why?
| | Transcription, Genetic | 2 | 2005 | 1432 | 0.040 |
Why?
| | Receptor Aggregation | 1 | 2000 | 10 | 0.040 |
Why?
| | Pneumothorax | 1 | 2021 | 54 | 0.040 |
Why?
| | Tumor Microenvironment | 1 | 2025 | 747 | 0.040 |
Why?
| | Reoviridae | 1 | 2000 | 38 | 0.040 |
Why?
| | Translocation, Genetic | 1 | 2021 | 127 | 0.040 |
Why?
| | Curriculum | 1 | 2007 | 1079 | 0.040 |
Why?
| | Chemokine CXCL9 | 1 | 2020 | 38 | 0.040 |
Why?
| | Syndrome | 1 | 2021 | 380 | 0.040 |
Why?
| | Germ-Line Mutation | 1 | 2021 | 180 | 0.040 |
Why?
| | Mutagenesis, Site-Directed | 1 | 2000 | 371 | 0.040 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2000 | 263 | 0.040 |
Why?
| | Mating Factor | 1 | 1999 | 2 | 0.040 |
Why?
| | Surveys and Questionnaires | 2 | 2022 | 6073 | 0.040 |
Why?
| | Receptors, Growth Factor | 1 | 1999 | 52 | 0.040 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2021 | 213 | 0.040 |
Why?
| | Proto-Oncogene Proteins | 1 | 2002 | 616 | 0.040 |
Why?
| | Cell Compartmentation | 1 | 1999 | 51 | 0.040 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2025 | 1432 | 0.040 |
Why?
| | Growth Substances | 1 | 1999 | 136 | 0.040 |
Why?
| | Insect Proteins | 1 | 1999 | 38 | 0.040 |
Why?
| | TRPP Cation Channels | 1 | 2019 | 76 | 0.040 |
Why?
| | Follow-Up Studies | 2 | 2020 | 5439 | 0.040 |
Why?
| | Transcriptional Activation | 1 | 2000 | 369 | 0.030 |
Why?
| | Fungal Proteins | 1 | 1999 | 137 | 0.030 |
Why?
| | Age of Onset | 1 | 2020 | 558 | 0.030 |
Why?
| | MAP Kinase Kinase 5 | 3 | 2003 | 4 | 0.030 |
Why?
| | Gene Expression Profiling | 1 | 2025 | 1792 | 0.030 |
Why?
| | Cytoskeleton | 1 | 1999 | 180 | 0.030 |
Why?
| | Chronic Disease | 2 | 2015 | 1827 | 0.030 |
Why?
| | Dexamethasone | 1 | 2020 | 368 | 0.030 |
Why?
| | Membrane Glycoproteins | 1 | 2000 | 495 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2020 | 970 | 0.030 |
Why?
| | Education, Medical, Graduate | 1 | 2022 | 568 | 0.030 |
Why?
| | DNA-Binding Proteins | 1 | 2005 | 1468 | 0.030 |
Why?
| | Mammals | 1 | 1999 | 288 | 0.030 |
Why?
| | Combined Modality Therapy | 1 | 2020 | 1271 | 0.030 |
Why?
| | Drug Therapy, Combination | 1 | 2020 | 1036 | 0.030 |
Why?
| | Microtubules | 1 | 1999 | 226 | 0.030 |
Why?
| | Receptors, Cell Surface | 1 | 2019 | 371 | 0.030 |
Why?
| | Intraoperative Period | 1 | 2017 | 69 | 0.030 |
Why?
| | Drosophila melanogaster | 1 | 1999 | 237 | 0.030 |
Why?
| | Hepatoblastoma | 1 | 2017 | 52 | 0.030 |
Why?
| | Incidence | 1 | 2024 | 2936 | 0.030 |
Why?
| | United States | 3 | 2022 | 16136 | 0.030 |
Why?
| | Anti-Inflammatory Agents | 1 | 2020 | 474 | 0.030 |
Why?
| | Stress, Physiological | 1 | 1999 | 450 | 0.030 |
Why?
| | Epidemiological Monitoring | 1 | 2016 | 70 | 0.030 |
Why?
| | Caenorhabditis elegans | 1 | 1999 | 330 | 0.030 |
Why?
| | Organizational Innovation | 1 | 2015 | 124 | 0.030 |
Why?
| | Neurilemmoma | 1 | 2014 | 26 | 0.030 |
Why?
| | Time Factors | 2 | 2018 | 7109 | 0.030 |
Why?
| | Saccharomyces cerevisiae | 1 | 1999 | 584 | 0.030 |
Why?
| | Interdisciplinary Communication | 1 | 2015 | 200 | 0.030 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2020 | 704 | 0.030 |
Why?
| | Parents | 1 | 2022 | 1394 | 0.020 |
Why?
| | Peptides | 1 | 1999 | 992 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2021 | 3416 | 0.020 |
Why?
| | MAP Kinase Kinase 7 | 2 | 2003 | 8 | 0.020 |
Why?
| | Neoplasm Staging | 1 | 2017 | 1488 | 0.020 |
Why?
| | Logistic Models | 1 | 2018 | 2126 | 0.020 |
Why?
| | Lymphoma | 1 | 2014 | 251 | 0.020 |
Why?
| | Analysis of Variance | 1 | 2015 | 1298 | 0.020 |
Why?
| | RNA, Messenger | 1 | 2000 | 2791 | 0.020 |
Why?
| | T-Lymphocytes | 1 | 2000 | 2012 | 0.020 |
Why?
| | Two-Hybrid System Techniques | 2 | 2003 | 59 | 0.020 |
Why?
| | Colorado | 2 | 2015 | 4595 | 0.020 |
Why?
| | Receptors, TNF-Related Apoptosis-Inducing Ligand | 2 | 2002 | 31 | 0.020 |
Why?
| | fas Receptor | 2 | 2002 | 91 | 0.020 |
Why?
| | Caspases | 2 | 2002 | 233 | 0.020 |
Why?
| | Inflammation Mediators | 1 | 2012 | 508 | 0.020 |
Why?
| | Transfection | 2 | 2003 | 916 | 0.020 |
Why?
| | Treatment Outcome | 2 | 2020 | 11821 | 0.020 |
Why?
| | Aged | 2 | 2022 | 26432 | 0.020 |
Why?
| | Receptor, IGF Type 1 | 1 | 2008 | 64 | 0.020 |
Why?
| | Ultrasonography | 1 | 2012 | 788 | 0.020 |
Why?
| | Chemistry, Pharmaceutical | 1 | 2008 | 116 | 0.020 |
Why?
| | Drug Design | 1 | 2008 | 180 | 0.020 |
Why?
| | Practice Patterns, Physicians' | 1 | 2017 | 1408 | 0.020 |
Why?
| | Bone Marrow Transplantation | 1 | 2008 | 301 | 0.020 |
Why?
| | Schools, Medical | 1 | 2007 | 158 | 0.010 |
Why?
| | Clinical Clerkship | 1 | 2007 | 111 | 0.010 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2008 | 545 | 0.010 |
Why?
| | Pancreatic Neoplasms | 1 | 2014 | 944 | 0.010 |
Why?
| | Histocompatibility Testing | 1 | 2005 | 124 | 0.010 |
Why?
| | Protein Binding | 2 | 2003 | 2244 | 0.010 |
Why?
| | Fos-Related Antigen-2 | 1 | 2005 | 1 | 0.010 |
Why?
| | Oligonucleotide Probes | 1 | 2005 | 48 | 0.010 |
Why?
| | Urokinase-Type Plasminogen Activator | 1 | 2005 | 25 | 0.010 |
Why?
| | Tetradecanoylphorbol Acetate | 1 | 2005 | 128 | 0.010 |
Why?
| | Prospective Studies | 1 | 2017 | 8123 | 0.010 |
Why?
| | Dimerization | 1 | 2005 | 174 | 0.010 |
Why?
| | Transplantation, Homologous | 1 | 2005 | 416 | 0.010 |
Why?
| | Faculty, Medical | 1 | 2007 | 309 | 0.010 |
Why?
| | Middle Aged | 2 | 2017 | 36619 | 0.010 |
Why?
| | Flow Cytometry | 1 | 2008 | 1163 | 0.010 |
Why?
| | Aged, 80 and over | 1 | 2016 | 8391 | 0.010 |
Why?
| | MEF2 Transcription Factors | 1 | 2003 | 51 | 0.010 |
Why?
| | Mink | 1 | 2003 | 11 | 0.010 |
Why?
| | Clinical Trials as Topic | 1 | 2008 | 1064 | 0.010 |
Why?
| | Graft vs Host Disease | 1 | 2005 | 283 | 0.010 |
Why?
| | Osmolar Concentration | 1 | 2003 | 165 | 0.010 |
Why?
| | Amino Acid Motifs | 1 | 2003 | 218 | 0.010 |
Why?
| | Multivariate Analysis | 1 | 2005 | 1543 | 0.010 |
Why?
| | Disease Models, Animal | 1 | 2012 | 4580 | 0.010 |
Why?
| | Caspase 3 | 1 | 2002 | 240 | 0.010 |
Why?
| | Cell Nucleus | 1 | 2005 | 584 | 0.010 |
Why?
| | Base Sequence | 1 | 2005 | 2123 | 0.010 |
Why?
| | Models, Biological | 1 | 2008 | 1761 | 0.010 |
Why?
| | MAP Kinase Kinase Kinase 3 | 1 | 2000 | 4 | 0.010 |
Why?
| | Fas-Associated Death Domain Protein | 1 | 2000 | 9 | 0.010 |
Why?
| | Caspase 8 | 1 | 2000 | 48 | 0.010 |
Why?
| | Caspase 9 | 1 | 2000 | 54 | 0.010 |
Why?
| | COS Cells | 1 | 2000 | 173 | 0.010 |
Why?
| | Molecular Sequence Data | 1 | 2005 | 2838 | 0.010 |
Why?
| | TNF-Related Apoptosis-Inducing Ligand | 1 | 2000 | 54 | 0.010 |
Why?
| | Oxidants | 1 | 2000 | 100 | 0.010 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2002 | 384 | 0.010 |
Why?
| | Caspase Inhibitors | 1 | 2000 | 81 | 0.010 |
Why?
| | Antigen-Presenting Cells | 1 | 2000 | 161 | 0.010 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2002 | 441 | 0.010 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2000 | 186 | 0.010 |
Why?
| | Hydrogen Peroxide | 1 | 2000 | 337 | 0.010 |
Why?
| | Mitosis | 1 | 1999 | 195 | 0.010 |
Why?
| | Lymphocyte Activation | 1 | 2000 | 1137 | 0.010 |
Why?
| | Epithelial Cells | 1 | 2003 | 1119 | 0.010 |
Why?
| | Oxidative Stress | 1 | 2003 | 1369 | 0.010 |
Why?
| | Kidney | 1 | 2003 | 1498 | 0.010 |
Why?
|
|
Garrington's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|